MicroRNA Expression Tied to Triple-Negative Breast Cancer in Latin America – Cancer Network

A grouping of 17 microRNA genes and their level of expression, can be used to distinguish between different cases of triple-negative breast cancer (TNBC), according to the findings of a study published inOncotarget.The results could also further explain the patterns of tumor development among certain ethnicities.

The study looked into the genomics of patients with cancer from Brazil. Fifty-four samples of non-treated primary breast tumors collected from the pathology tumor bank at the Hospital Nossa Senhora das Graas, in Paran. Those samples were split between patients with TNBC and those with other tumor forms.

The panel of miRNAs identified demonstrated the impact of CNAs in miRNA expression levels and identified miRNA target genes potentially affected by both CNAs and miRNA deregulation, the authors wrote. These targets, involved in critical signaling pathways and biological functions associated specifically with the TNBC transcriptome of Latina patients, can provide biological insights into the observed differences in the TNBC clinical outcome among racial/ ethnic groups, taking into consideration their genetic ancestry.

The DNA and RNA were isolated, purified, and quantified. Ancestral analysis was performed on single nucleotide polymorphisms (SNPs) using the SNP chip, Illumina Infinium QC Array.

Genome-wide copy number profiling was made possible by array-CGH using the SurePrint G3 Human CGH Microarray made by Agilent. The Global miRNA expression profiling was then performed using the NanoString nCounter technology Human v2 miRNA Expression Assay. The 2 data sets were integrated, especially through the identification of copy number alterations (CNAs), according to the study results.

The final tally produced a 17-microRNA panel which showed elevated expression in the patients with TNBC. Whats more, the majority of the target RNA molecules were significantly correlated with the aggressiveness of the tumor, including its advanced grade and stage.

The panel of miRNAs we identified indicate potential, critical cancer-related pathways and gene networks that could be targeted for the treatment of TNBC in Latinas, once our findings are validated by larger studies, said Luciane Cavalli, the lead author, of Georgetown Lombardi, in a statement released Tuesday.

The findings could eventually prove actionable for screening, and in the clinic added Cavalli.

Targeting these genetic alterations, that represent the unique biology of their tumors, may lead to more efficient treatments, which could increase the longevity of Latina women who do not have many therapeutic options to fight this very aggressive disease, she said.

Read more:

MicroRNA Expression Tied to Triple-Negative Breast Cancer in Latin America - Cancer Network

Thinking deep thoughts has impact on life span – Mother Nature Network

Are you always deep in thought, thinking nonstop about the world around you? You might want to cut back on that. Researchers at Harvard Medical School just published a study in the journal Nature comparing the brains of people who had died in their 60s and 70s to those who had died over the age of 100.

They found that all roads lead to REST (RE-1 Silencing Transcription), that is, a protein that helps to calm your brain. This protein is enormously important to our brain health: Defects in REST have been linked to Huntington's disease and epileptic seizures, and it's also found in reduced amounts in elderly people with Alzheimer's disease.

REST has been found to quiet brain activity, and it can also protect those with dementia and other stresses.

It is currently not possible to measure REST in a living brain, so scientists relied on donated brain tissue from hundreds of people who died from ages 60 to over 100.

Study author Bruce Yankner, professor of genetics at Harvard, found that the differences in brains were immediately compelling: The longest-living people had lower expression of genes related to neural excitation. REST regulates these genes, and the centenarians' brain cells contained higher amounts of the protein than those who died younger.

It was extremely exciting to see how all these different lines of evidence converged, says study co-author Monica Colaicovo, also a professor of genetics at Harvard.

Socrates would likely disagree with the notion that too much deep thinking can lead to an earlier death. (Photo: DIMSFIKAS [CC by SA 3.0]/Wikimedia Commons)

While the brain's neural activity has long been explored in issues like dementia and epilepsy, this is the first evidence to reveal how it affects human longevity.

An intriguing aspect of our findings is that something as transient as the activity state of neural circuits could have such far-ranging consequences for physiology and life span, says Yankner.

Besides looking at hundreds of human brain tissue samples, the Harvard team also experimented with worms and mice by decreasing and increasing their mental activity. All of these experiments found that changing neural excitations affected life spans and creatures without the precious protein REST in their brain died at a faster rate.

It's still unclear how a person's exact thoughts, feelings or behavior can affect their longevity. Numerous studies have linked optimism to a longer life, and suggested a positive outlook can even affect your body's chemical balance.

Perhaps most striking about the study is that it contradicts many long-held popular beliefs about our brains and aging. Doctors have stressed that keeping your mind active, whether it's with brain-training games or a daily crossword puzzle, can also help you live longer. But this study's findings suggest that not all thoughts are equal.

The completely shocking and puzzling thing about this new paper is brain activity is what you think of as keeping you cognitively normal. Theres the idea that you want to keep your brain active in later life, neuroscientist Michael McConnell told The Washington Post.

The researchers hope this study will encourage more research on neural overactivity and what types of therapeutic interventions are possible. But until then, just to be safe, it's probably best not to think too hard about it.

Thinking deep thoughts has impact on life span

A recent Harvard study finds that neural activity is a new player when it comes to human aging.

See original here:

Thinking deep thoughts has impact on life span - Mother Nature Network

Nanomedicines Market 2027 In-Depth Analysis with Booming Trends and Supporting Growth with Top Key Players AstraZeneca, Cristal Therapeutics, Ablynx ,…

Nanomedicine involves the use of nanoscale materials, such as biocompatible nanoparticles and nanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism. These can pass directly through the cellular membranes and interact with the cellular DNA and proteins, giving better desired results as compared to the traditional form of medicines. These nanomedicines are normally used across applications such as, diagnosis, targeted drug delivery and imaging.

The The Insight Partners market research report provides a comprehensive picture on Nanomedicines Market, from the global viewpoint, offering a forecast and statistic in terms of revenue during the forecast period. The report covers a descriptive analysis with detailed segmentation, complete research and development history, latest news and press releases. Furthermore, the study explains the future opportunities and a sketch of key players operating in the Nanomedicines market.

Nanomedicines Market

Get Sample PDF https://www.theinsightpartners.com/sample/TIPRE00004589/

Leading Nanomedicines marketPlayers:

Detailed segmentation of the market, on the basis of Type and Application and a descriptive structure of trends of the segments and sub-segments are elaborated in the report. It also provides the market size and estimates a forecast from the year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The report also provides exhaustive PEST analysis for all five regions after evaluating political, economic, social and technological factors effecting the Nanomedicines marketThe report assists in determining and analyzing the key market players portfolios with information such as company profiles, components and services offered, financial information for last three years, key developments in past five years, and helps in constructing strategies to gain competitive advantage. The market payers from Nanomedicines market are anticipated to gain lucrative growth opportunities in the future with the rising demand at the global level. Below mentioned is the list of few companies engaged in the Nanomedicines market.

The Nanomedicines market report is a combination of qualitative as well as quantitative analysis which can be broken down into 40% and 60% respectively. Market estimation and forecasts are presented in the report for the overall global market from 2019 2027, considering 2017 as the base year and 2019 2027 forecast period. Global estimation is further broken down by segments and geographies such as North America, Europe, Asia-Pacific, Middle East & Africa and South America covering major 16 countries across the mentioned regions. The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market.

Purchase This Report at https://www.theinsightpartners.com/buy/TIPRE00004589/

The report also includes the profiles of key equine healthcare market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Answers that the report acknowledges:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:Call: +1-646-491-9876Email:sales@theinsightpartners.com

Website:https://www.theinsightpartners.com/

More here:
Nanomedicines Market 2027 In-Depth Analysis with Booming Trends and Supporting Growth with Top Key Players AstraZeneca, Cristal Therapeutics, Ablynx ,...

Healthcare Nanotechnology (Nanomedicine) Market Competition, Status and Forecast, Market Size, Key Players, Regions, Growth Rate, Type, Application by…

The Healthcare Nanotechnology (Nanomedicine) Market report provides detailed information about key market dynamics such as detailed coverage, key trends, opportunities, historical and forecast market information, demand, application details, company shares and detailed information about Healthcare Nanotechnology (Nanomedicine) market structure. This market research report shows specific facts and figures on how the Healthcare Nanotechnology (Nanomedicine) market will grow over the forecast period.

This market research study is significant for manufacturers in the Healthcare Nanotechnology (Nanomedicine) market, including Healthcare Nanotechnology (Nanomedicine) stakeholders, distributors, suppliers, and investors, and it can also help them understand applicable strategies to grow in the Healthcare Nanotechnology (Nanomedicine) market. Stakeholders, investors, industry experts, as well as business researchers can influence the information and statistics offered in the market research report.

Get a Sample Copy of the Report at https://www.industryresearch.co/enquiry/request-sample/13339023

About Healthcare Nanotechnology (Nanomedicine) Market Report: Nanomedicine is a promising mode of cancer treatment. With the advantage of the properties of matter at nanoscale, nanomedicine promises to develop innovative drugs with greater efficacy and lesser side effects than standard therapies.

Top manufacturers/players: Abbott Laboratories, Combimatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Mallinckrodt Plc, Merck & Company Inc., Nanosphere Inc., Pfizer, Inc., Celgene Corporation

Healthcare Nanotechnology (Nanomedicine) Market Segment by Regions-

The Healthcare Nanotechnology (Nanomedicine) Market report delivers a basic overview of the industry including its definition, applications and manufacturing technology. Also, the Healthcare Nanotechnology (Nanomedicine) Industry report explores the international Major Market players in detail.

Healthcare Nanotechnology (Nanomedicine) Market Segment by Type:

Healthcare Nanotechnology (Nanomedicine) Market Segment by Applications:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13339023

Through the statistical analysis, the Healthcare Nanotechnology (Nanomedicine) Market report depicts the global market of Healthcare Nanotechnology (Nanomedicine) Industry including capacity, production, production value, cost/profit, supply/demand and import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

Table of Contents:

1 Market Overview

2ManufacturersProfiles

3GlobalHealthcare Nanotechnology (Nanomedicine)Sales,Revenue,MarketShareandCompetitionbyManufacturer(2017-2018)

4GlobalHealthcare Nanotechnology (Nanomedicine)MarketAnalysisbyRegions

5NorthAmericaHealthcare Nanotechnology (Nanomedicine)byCountry

6EuropeHealthcare Nanotechnology (Nanomedicine)byCountry

7Asia-PacificHealthcare Nanotechnology (Nanomedicine)byCountry

8SouthAmericaHealthcare Nanotechnology (Nanomedicine)byCountry

9MiddleEastandAfricaHealthcare Nanotechnology (Nanomedicine)byCountries

10GlobalHealthcare Nanotechnology (Nanomedicine)MarketSegmentbyType

11GlobalHealthcare Nanotechnology (Nanomedicine)MarketSegmentbyApplication

12Healthcare Nanotechnology (Nanomedicine)MarketForecast(2019-2024)

13SalesChannel,Distributors,TradersandDealers

14ResearchFindingsandConclusion

15 Appendix

Continued

Purchase This Report (Price 3480 $ USD for a Single-User License) https://www.industryresearch.co/purchase/13339023

Contact Us:

Name: Ajay More

Phone:US +1424 253 0807 /UK +44 203 239 8187

Email:[emailprotected]

In the end, the Healthcare Nanotechnology (Nanomedicine) Market report makes some important proposals for a new project of Healthcare Nanotechnology (Nanomedicine) Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2013-2023 Global and Chinese Healthcare Nanotechnology (Nanomedicine) Market covering all important parameters.

Our Other Reports:

Lactic Starter Culture Industry: Global Market Overview, Shares, Growth, Demand and Forecast Report 2023

Core Drill Market Report 2019 With Top Countries Data: Analysis, Price and Gross Margin, Market Size, Competition by Manufacturers

Aviation Obstacle Lighting Industry: Global Market Overview, Shares, Growth, Demand, market Size, Production, Types & Applications and Forecast Report 2024

Sickle Cell Disease Treatment Market Business Opportunities, Market, Trend, Growth, Revenue, Manufacturers and Forecast from 2019-2023

Go here to see the original:
Healthcare Nanotechnology (Nanomedicine) Market Competition, Status and Forecast, Market Size, Key Players, Regions, Growth Rate, Type, Application by...

Nanomedicine Market Overview On Product Performance 2025 – Health News Office

Transparency Market Research (TMR) has published a new report titled, Microcatheter Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026. According to the report, the global microcatheter market was valued atUS$ 162.3 Mnin 2017 and is anticipated to reach nearlyUS$ 304.5 Mnby 2026, expanding at a CAGR of around 7.5% from 2018 to 2026. Rise in adoption of minimally invasive procedures, technological advancements, increase in target patient population are likely to fuel the global microcatheter market from 2018 to 2026. Improved hospital infrastructure in developed markets such asNorth AmericaandEurope, rise in medical tourism inAsia Pacific, and advantages of minimally invasive procedures are expected to drive the microcatheter market during the forecast period.

Get PDF Brochure for Research Insights athttps://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35942

Rise in Adoption of Minimally Invasive Surgeries to Propel Market

Embolization is a minimally invasive surgery that marks a significant advancement in medical technology. Embolization procedures are used in the treatment of cerebral aneurysms and peripheral vascular diseases. Adoption of minimally invasive surgeries has been increasing significantly due to various advantages including less post-operative pain, less blood loss, reduced hospital stay, and faster recovery. This is likely to propel the microcatheters market during the forecast period

Increase in target patient population and Technological Advancements

Increase in the geriatric population, which is prone to neurovascular and cardiovascular diseases, is projected to drive the microcatheter market. According to the National Institute of Neurological Disorders and Stroke, nearly 30,000 people in the U.S. suffer a brain aneurysm rupture each year.

Request a Custom Report athttps://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=35942

According to the American Heart Association, cardiovascular diseases account for around 17.3 million deaths each year, which is expected to increase to about 23.6 million by 2030. Technological advancements such as introduction of double coaxial guiding catheter technique, which is employed to treat chronic total occlusion (CTO) is driving the market. This technique places one guide catheter inside another. The advantages of passive support provided by a large guide catheter are combined with the ability to actively engage the smaller catheter into the target vessel. These developments are likely to add value to microcatheters and drive the global microcatheter market

Product Recall and Stringent Regulatory Requirement to Restrain Market

Several microcatheters witnessed recalls in the last few years due to defects in the products. This is expected to impact the demand for these devices. Product recalls also have a negative impact in the future profitability and adoption of these procedures by patients. InOctober 2016, Medtronic recalled certain lots of pipeline embolization device, Alligator retrieval device, and X-Celerator hydrophilic guide wire. The recall also included the stylet containing UltraFlow flow directed microcatheters and marathon flow directed microcatheters. Product approvals and launch of medical devices are governed by various regulations established by the U.S. FDA and other regulatory bodies operating in each country. The U.S. FDA continues to increase testing and documentation required for the clearance of devices. Similar regulations are noted in the European Union (EU),Japan, andChina. The various levels of approval processes can delay the product release in the market, which could have a negative impact on revenue

Request a Sample of Microcatheter Market:https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=35942

Market inAsia Pacificto Register Exponential Growth

In terms of revenue, the microcatheter market inAsia Pacificis expected to expand at a CAGR of 7.8% during the forecast period. Increase in product launches is expected to drive theAsia Pacificmicrocatheter market. In 2018, ASAHI received chronic total occlusion (CTO) approvals for Corsair Pro Micro catheters and its Coronary Guide Wires to the include MIRACLEbros series, CONFIANZA series, FIELDER series, and Gaia series. According to the World Health Organization, most of the financial burden in health care is the responsibility of governments of countries inAsia Pacific. For instance, inChina, more than 95% of health care coverage is under public insurance schemes, which lay emphasis on catastrophic diseases and inpatient services.

Request For Discount On This Report:https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=35942

Boston Scientific Corporation,Codman Neuro, Medtronic, Biometrics and Asahi InteccUSA, Inc. to Lead the Market

The report also provides profiles of leading players operating in the global microcatheter market, which include Boston Scientific Corporation,Codman Neuro, Medtronic, Biometrics, Asahi InteccUSA, Inc., Merit Medical Systems, Inc., Stryker, Terumo Medical Corporation, Tokai Medical Products, Inc., and Penumbra, Inc.

View post:
Nanomedicine Market Overview On Product Performance 2025 - Health News Office

TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY Annual Meeting and in International Journal of Nanomedicine TLC590 showed…

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, recently presented data at the American Society of Anesthesiologists (ASA) ANESTHESIOLOGY annual meeting from a Phase I/II clinical trial which showed TLC590 to yield more immediate and long-lasting pain reduction than ropivacaine. In addition, in vivo findings in which TLC590 showed no dose-related toxicity and other preclinical data were recently published in the International Journal of Nanomedicine. TLC590 is a non-opioid, BioSeizer formulation of ropivacaine with the aim to manage postsurgical pain for four to seven days with a single dose, potentially deterring the use of opioids following surgery.

At ANESTHESIOLOGY 2019, which took place October 19-23 at the Orange County Convention Center in Orlando, FL, principal investigator Todd Bertoch, MD, Chief Medical Officer at JBR Clinical Research, a CenExel Clinical Research Center of Excellence, presented findings from a Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study of TLC590 following inguinal hernia repair.

Highlights from the e-poster presentation are as follows:

I am delighted to have had the opportunity to present these fantastic results, said Dr. Todd Bertoch. As a clinical researcher specializing in pain, it is so rewarding to be able to share findings that provide hope for a real, substantive weapon in the war against opioids. Clinicians have been waiting patiently for safe, easily administered, very long acting local anesthetics with a rapid onset. These data suggest that we may have found one.

Results of studies evaluating the release profile of TLC590 in vitro and its pharmacokinetics and anesthetic effect in vivo were recently published in the International Journal of Nanomedicine.

Highlights from the publication article are as follows:

The poster presentation and full text article can be accessed under Publications in the Pressroom section of TLCs website at http://www.tlcbio.com.

About TLC590

TLC590 is a non-opioid, BioSeizer sustained release formulation of ropivacaine designed to prolong the retention time of ropivacaine around the injection site as a drug depot, simultaneously extending its therapeutic period and reducing unwanted systemic exposure. A Phase II, randomized, double-blind, comparator- and placebo-controlled clinical trial to evaluate the safety, pharmacokinetics and efficacy of TLC590 following bunionectomy is ongoing.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD). TLC believes that its deep experience with liposome science allows a combination of onset speed and benefit duration, improving active drug concentrations while decreasing unwanted systemic exposures. TLCs BioSeizer technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX active drug loading technology is designed to alter the systemic exposure of a drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients, and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, without limitation, statements regarding TLCs expectations regarding the clinical development of TLC590, the clinical benefits of TLC590 for postsurgical pain management, the timing, scope, progress and outcome of the clinical trials, and the anticipated timelines for the release of clinical data. Words such as may, believe, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and TLC590 or any of our other product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLCs annual report on Form 20-F for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLCs expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

Read the original here:
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY Annual Meeting and in International Journal of Nanomedicine TLC590 showed...

New CBE professor Bardhan to bring image-guided techniques to fight against disease College of Engineering News Iowa State University – Iowa State…

Rizia Bardhan

With a research specialty in nanomedicine and nanophotonics and designing materials that fight diseases using image-guided techniques Rizia Bardhan will join the faculty of the Department of Chemical and Biological Engineering in January, 2020.

Bardhan, who has been hired as a tenured associate professor, comes to Iowa State from Vanderbilt University, where she has been an assistant professor in the Department of Chemical and Biomolecular Engineering since 2012.

Her research focuses on designing nanomaterials that can be activated by external stimuli and then utilize them for biomedical imaging, and image-guided drug delivery and immunotherapies across many disease models, including cancer, neurodegenerative disease and infection. She also develops point of care diagnostics that she is currently applying for early detection of preterm birth in pregnant women. Click here for more on her current research.

Prior to joining the faculty of Vanderbilt University she was a postdoctoral fellow at The Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA.

She received a B.A. in mathematics and chemistry at Westminster College, Fulton, Missouri, in 2005 and a Ph.D. in chemistry at Rice University in 2010 under the guidance of Prof. Naomi Halas, a pioneer in nanophotonics and plasmonics.

In the 2020 spring semester at Iowa State she will teach ChE 381, chemical engineering thermodynamics.

Outside of research and teaching, Bardhan enjoys spending time outdoors with her two sons Elan (3) and Jonah (5), and husband Cary Pint, who is also a new Iowa State University faculty member, joining the Department of Mechanical Engineering in January.

See original here:
New CBE professor Bardhan to bring image-guided techniques to fight against disease College of Engineering News Iowa State University - Iowa State...

Global Nanomedicine Market To Witness Steady Growth During The Forecast Period 2019-2028 – The State News – BBState

New York City, NY: October 23, 2019 Published via (Wired Release) Global Nanomedicine Market Research Reportrepresents the proficient analysis of Nanomedicine industry providing a competitive study of leading market players, market growth, consumption(sales) volume, key drivers and limiting factors, future projections for the new-comer to plan their strategies for business. Further, the report contains the study of Nanomedicine market ups and downs of the past few years and forecasts sales investment data from 2019 to 2028.

The Nanomedicine Report outlining the vitals details which are based on manufacturing region, top players, type, applications and so on will give a transparent view of Industry. The important presence of different regional and local players of Nanomedicine market is tremendously competitive. The Nanomedicine Report is beneficial to recognize the annual revenue of key players, business strategies, key company profiles and their benefaction to the market share.

Download Free Sample Copy of Nanomedicine Market Report:https://marketresearch.biz/report/nanomedicine-market/request-sample

Top Manufacturers Are Covered in This Report:Abbott Laboratories, Ablynx NV, Abraxis BioScience, Inc., Celgene Corporation, Teva Pharmaceutical Industries Limited, GE Healthcare Limited, Merck & Co., Inc., Pfizer Inc., Nanosphere, Inc., Johnson & Johnson Services, Inc.

This research report contains the pictorial representation of important data in the form of graphs, figures, diagrams and tables to make simplified for the users to understand the Nanomedicine market new trends clearly.

Geographically, report on Nanomedicine is based on several regions with respect to Nanomedicine export-import ratio of the region, production and sales volume, share of Nanomedicine market and growth rate of the industry. Major regions included while preparing the report areNorth America, Latin America, Europe, Middle East, Africa, and Asia Pacific.

The leading players in Nanomedicine industry are estimated to ahead on these opportunities to invade the global market. Nanomedicine market size and revenue of key players is assessed using the Bottom-up way.

Reasons for Buying Global Nanomedicine Market Report

* Report provides in-depth study on changing Nanomedicine market dynamics.

* Report offers Pin Point study on distinct factors driving and constraining industry growth.

* Technological innovation in market to study Nanomedicine market growth rate.

* Estimated Nanomedicine market growth depending on the study of historical and the present size of the industry.

Customize Report AndInquiry For The Nanomedicine Market Report:https://marketresearch.biz/report/nanomedicine-market/#inquiry

Report Table of Content Gives Exact Idea about Global Nanomedicine Market Report:

Chapter 1explains Nanomedicine report necessary market surveillance, product price structure, and study, market scope and size forecast from 2019 to 2028. Although, Nanomedicine market activity, factors impacting the growth of business also complete analysis of current market holders.

Chapter 2offers detailing of top manufacturers of Nanomedicine market with their share, sales, and revenue.

Chapters 3, 4, 5studies Nanomedicine report competitive study based on the type of product, their regional sales and import-export study, the annual growth ratio of the market and the coming years study from 2019 to 2028.

Chapter 6offers a detailed analysis of Nanomedicine business channels, Nanomedicine market investors, vendors, Nanomedicine suppliers, dealers, Nanomedicine market opportunities and threats.

This content has been distributed via WiredRelease press release distribution service. For press release service inquiry, please reach us at[emailprotected]

Contact Us:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

Read the original post:
Global Nanomedicine Market To Witness Steady Growth During The Forecast Period 2019-2028 - The State News - BBState

Have a beef with vegetarianism? Find out what all the mooing is… – Communities Digital News

SAN DIEGO Ever wonder why we are hearing more and moreabout vegetarianism and veganism?Vegetarianism in Americas 2017 study showed that 3.2 percent of all USadults, or approximately 7.3 million Americans, follow a plant-basedvegetarian diet. And 0.5 percent or 1 million persons are vegans. That might be the reason

With a national trend predominantly spawned by Millennials, and GenerationZs, people across the country are catching this trend.

The Mayo clinic, in their Healthy Lifestyle segment, helped to provideclarity to the variety of vegetarian diet types:

Vegetarian diets tend to be comprised of fewer processed foods. These foods arelower in calories, sugar, fat, cholesterol and sodium in the main.

According to the Mayo Clinic, a quality vegetarian diet consists of fruitsvegetables, whole grains, dairy (if permitted), protein sources andhealthy oils.

Meat for Vegetarians

Published in Harvard Health, the article Becoming a Vegetarian, speculates that a plant-based vegetarian diet helps reduce heart disease, some formsof cancer, diabetes. It may also help maintain a healthy weight level.

One of the greatest challenges vegetarians face is maintaining an adequateintake of protein.

According to Healthline, proteins are the building blocks of our organs, muscles, skin, hormonesand more.

Companies like Beyond Meat,Greenleaf Foods, Applegate Farms, Hormel Foods currently invest millions of dollars and more to findalternative solutions ensuring proper protein alternatives and otherhealth-enhancing properties.

For vegetarians today, the challenges and choices are becoming easier as morealternatives are finding creative and tasty solutions.

Restaurants are stepping up and offering vegetarian solutions forsatisfying a palate. These include a variety of casual fast-food chainsthat offer scrumptious alternatives to the traditional beef orchicken burger.

Healthline offers further recommendations for attaining the 46 grams ofdaily protein for women and 56 grams of daily protein for men:

Be certain to read the ingredients on food labels. Some explore vegetarian options, helping to ensure compliance with the vegetarian diet of choice.

An occasionalblood test for key elements is a simple process provided by your medical professional to ensure adequate vitamin, mineral and protein levels,

According to Veganbits, there are many reasons why Americans areturning to vegetarianism.

With health being the top reason, animal protection and personal disgust abouteating animals ranked close second and third reason. Other reasons mentioned included environmental, social and religious.

Jane Goodall

Whatever our age, socio-economic status, faith, gender, culture, orbeliefs regarding the environment, vegetarianism could ultimately become a unifying factor in creating a healthier, safer and more economicallycountry and a more stable world.

It would be wonderful if country-by-country, we could eliminate hunger as the food supply becomes more greatly plant-based. This could help create new sectorjobs, technologies, sustainable independence, more availability of foodand the reduction of disease.

Until next time, enjoy the ride in good health!

Headline image: The vegan Amy Burger at Amys Drive-Thru in Rohnert Park, California. Image via Wikipedia Commons, CC 2.0 license.

View post:
Have a beef with vegetarianism? Find out what all the mooing is... - Communities Digital News

Fake Meats Are Hot, but Are They Healthy? | BU Today – BU Today

The vegan chorizo in a taco served up at Taqueria El Barrio on Comm Ave poses a delicious dilemma.

The red, granular imitation chorizo looks just like Mexican-style pork sausage, and yet it cannot remotely be described as a health food. What is it made from? Nothing on the menu indicates its ingredients and the staff knows only that the main ingredient is soy.

Mystery (un)meat and new vegan faux meat options abound around the BU campus, from dining halls and the freezer section of supermarkets to Dunkin shops, which will roll out a new Beyond Sausage breakfast sandwich in early November.

With growing numbers of millennials and Generation Zers demanding affordable, cruelty-free foods and weighing the environmental impact of their day-to-day eating choices, there are now more options than ever, from Impossible Burgers and Incogmeato brand chicken nuggets to New Wave Foods lab-cultured shrimp, which it bills as shellfish evolved. And college and university campuses have become ground zero for the mock-meat movement.

If people gave up meat, it would have such a big impact on the environment, says Hannah Ferguson (CAS23), who decided to become a vegetarian when she arrived at BU. I dont miss meat.

Its definitely super, super easy now to be vegan, says Gianina Padula (Sargent21), who says dining options were one of the factors she weighed in choosing a college. Its made me more conscious of what I put in my body.

But since colleges like BU, with 11,000 students on a meal plan, are where questions get asked, and often answered through years or decades of research, here are two to consider: what if fake meat isnt so good for the planet after all? And what if its not that healthy either? What if its a trend, like the fat-free foods deluge of the 1990s that gave us potato chips made with Olestra and joyless Snackwell cookies?

As nutritionist Joan Salge Blake (Sargent84, Wheelock16), a Sargent College of Health & Rehabilitation Sciences clinical professor of nutrition, says: Dont just assume the new options are healthier than the cow.

Its too early to know the answer for sure, but vegetarianism and veganism have evolved from being a personal health statement to a political one about the planets well-being. Sales of plant-based meat rose nearly 40 percent, to $801 million, between 2017 and 2019, according to the Good Food Institute, an industry group. Kara Nielsen (MET06), vice president of trends and marketing at Silicon Valleybased CCD Innovation, says young consumers are driving the shift, impatient for new ways to address their concerns that traditional agriculture will not be able to support the planets food needs without at the same time destroying the planet.

Theyre big consumers of media and [theyve] seen all the movies and videos that have shed light on the horrors of factory farming, so theyve been influenced by that, Nielsen says. This is a way they can exert power and control using their diet.

Meat substitutes increasingly promise a bizarre meta meat-eating experience.

Take the bleeding Impossible Burger, made with red, plant-based heme to make it taste meaty and look more like a burger. Its now available in grocery stores and at Burger King, and is one of the plant-based state-of-the-art options in BU dining halls, thanks to student demand.

Its rival, Beyond Meat, calls itself the future of protein and is featured on the menus of McDonalds and Subway. The alternative protein market is growing and companies like San Franciscobased Just are using animal cells, not a slaughtered animal, to make cultured chicken in a laboratory.

A promotional video even shows Justs employees eating its engineered chicken foodstuff at a picnic table while a chicken named Ian, whose cells helped create the food theyre eating, struts around the grassy yard.

Its surreal, but the industry calls these pseudo chicken nuggets and plant-based burgers clean meat, because they are created in a laboratory, not raised in a factory farm. The companies behind the new ventures heavily promote themselves as an environmentally friendly option, as well as a virtuous one.

Our planet cannot afford to supply the water, fuel, pesticides, and fertilizer that industrialized animal production requires, the Just website says. It cant afford the polluted water or the biodiversity loss. It cant afford the moral inconsistencies.

Some research has shown that moving away from livestock and poultry would reduce greenhouse gases. Joseph Poore, a doctoral student studying the environment at the University of Oxford, found that avoiding meat and dairy is the single biggest way to reduce your environmental impact, not just on greenhouse gas emissions, but on land use, biodiversity loss, water pollution, pesticide use, antibiotic use and a range of other issues.

Another study, commissioned by Beyond Meat and conducted by the Center for Sustainable Systems at the University of Michigan, found that Beyond Meats burgers generated 90 percent less greenhouse gas emissions, among other environmental benefits.

The drawbacks of red meats and pork, as well as processed meats like salami and frankfurters, which the World Health Organization classifies as carcinogenic, are well documented.

But fake meats also come with many health and environmental unknowns that will take years to understand. An article by researchers at Harvards T. H. Chan School of Public Health that looked at whether plant-based meat alternatives can be part of a healthy and sustainable diet was published in the August issue of the Journal of the American Medical Association. Their conclusion: the answer remains far from a given due to a lack of rigorously designed and independently funded studies.

Take heme, the much-publicized ingredient in the Impossible Burger that the company says makes meat taste like meat and is something weve been eating and craving since the dawn of humanity. Impossible Foods derives its heme from soy plants using a fermentation process and genetically engineered yeast.

Sean J. Elliott a College of Arts & Sciences professor of chemistry, a heme chemist, and a vegetarian, says heme is a common molecule used in biochemistry research and is found not just in animals and soy, but in insects and bugs that dont necessarily taste like meat. The heme thats used by Impossible Foods isnt just hemeits heme delivered to your burger using a heme-binding protein called leghemoglobin. That raises questions for him about whether its truly the factor responsible for the meaty craveability of the product.

Although he says hes enjoyed Impossible Burgers on a couple of occasions, he also says the fermentation process used to create heme leaves behind a cocktail of leftovers along with leghemoglobin if the product is produced at an industrial scale.

Its easy to stay focused on the red heme, because its pretty. As a chemist, I have to think so, Elliott says. And for marketing, it gives you something easy to focus on instead of some of the other more complicated intellectual property that [Impossible Foods] doesnt necessarily want all their competition to know aboutlike how you make those yeast strains do the stuff that they do.

From a health perspective, Salge Blake says, many alternative meats are highly processed and made with unfamiliar ingredients, something health professionals have steered people away from for decades. A Burger King Impossible Whopper and a regular Whopper have about the same calories (630 vs. 660) and both contain unhealthy amounts of saturated fat and salt and more saturated fat than a regular hamburger made from lean beef.

It can also be tricky to discern what to eat when even traditional health advice about meat is called into question. Last month, a surprising study challenged decades of nutrition advice by telling consumers that forgoing red meat and pork offers only small health benefits, contradicting decades of nutrition advice and sowing confusion. On the heels of the report, it was revealed that the studys lead author, Bradley C. Johnston, an epidemiologist at Canadas Dalhousie University, has funding ties to the meat and food industry.

Salge Blake recommendsthis will sound familiara balanced diet rich in vegetables and fruits as well as lean meats and proteins. And she cautions against taking an extreme approach when it comes to health trends that also claim to save the planet, because it can create anxiety over food choices.

Im not a fan of the clean-eating thing, because it makes people crazy, she says. Students are thinking, I cant have all these worlds coming at me at one time.

Christopher L. Bee, BU culinary director, has a big job. The University has more than 11,000 students on its food plan, and they are vegan, vegetarian, carnivore, pescatarian, and increasingly flexitarian. (No fruitarians yet. Yes, thats a thing.) Keeping everyone satisfied is a challenge, especially when students are ranking colleges by which ones have the best dining halls.

Bee offers Impossible Burgers and a wide variety of vegetarian and vegan dishes, as well as organic, fair-trade, free-range, and sustainably harvested foods. There are dining halls that offer as many as 10 different types of milk and milk substitutes, with oat milk the latest addition.

People are less afraid of the word vegan, says Bee, recalling the era when tofu and seitan seemed exotic. But laboratory food isnt what we like to do.

He says hes interested in offering vegetarian fare thats nutritious and familiar, and hes recently offered a special vegan-vegetarian station training class for Dining Services chefs. And hes got another on plant-forward cooking planned. (According to Plant-Forward Global 50, plant-forward is a style of cooking and eating that emphasizes and celebrates, but is not limited to, plant-based foodsincluding fruits and vegetables.)

The University already sources more than 20 percent of its food from local farmers, more than 80 percent of the seafood it serves is certified as traceable or sustainably caught or farmed, and nearly 20 percent of its meat and poultry products are certified as humanely raised. Ground beef, hamburgers, and hot dogs are from grass-fed animals, pork is from gestation crate-free animals. Find a full list here.

It will be college and university researchers who will ultimately untangle the environmental and health benefits, if any, related to the new meat substitutes hitting the market. But Bee, himself a carnivore, says he thinks the vegan meatballs cooked by his chefs at Fresh Fuel at Granby Commons compete favorably with meat and vegetarian options, and theyre cooked using eggplant, garlic, and lentils and are very flavorful.

We do serve the Impossible Burger, but we can get the same results using food, while still making a difference, he says.

Read the original:
Fake Meats Are Hot, but Are They Healthy? | BU Today - BU Today

Insights into Parkinson’s Onset May Lie in New Model of Cell Aging and Damage – Parkinson’s News Today

A newly created model helps to clarify the processes by which cells grow old and die, and which are known to be involved in the onset of neurodegenerative disorders likeAlzheimers and Parkinsons disease.

The study describing this model, Proteostasis collapse is a driver of cell aging and death, was published in PNAS.

To remain healthy, cells must be able to produce proteins and chaperone them: keeping proteins correctly folded, and destroying those that arent.

But as cells age, oxidative stress an imbalance between reactive and inflammatory free radicals andthe ability of cells to detoxify them slowly leads to the accumulation of irreparably damaged proteins inside cells that eventually overwhelm their quality control mechanisms.

Irreparably damaged proteins accumulate with age, increasingly distracting the chaperones from folding the healthy proteins the cell needs. The tipping point to death occurs when replenishing good proteins no longer keeps up with depletion from misfolding, aggregation, and damage, the researchers wrote.

Investigators with the Laufer Center for Physical & Quantitative Biology at Stony Brook University created a model that is able to predict the lifespan of the round worm Caenorhabditis elegans, an animal model often used in aging studies, based on its protein quality controlmechanisms.

In their study, scientists showed their models predictions matched the results of experiments they performed on round worms to assess the effects of oxidative damage on the animals lifespan.

In one experiment, they found that animals raised at a temperature of 20 degrees Celsius (about 68 degrees Farhenheit) had an average lifespan of 20 days. Worms were raised at higher temperatures and in the presence of free radicals (byproducts of oxidative stress), however, had lifespans of only a few hours.

As the cell is stressed by heat, proteins unfold, misfold, and aggregate. Chaperones are recruited, but with age, the synthesis [production] of good protein and the chaperoning of those spontaneously unfolding ultimately succumb to damage levels, at which bad protein becomes overwhelming, the researchers said.

Their work also found that mutant animals with more chaperones or proteasomes a complex of enzymes responsible for the destruction of unnecessary or damaged proteins lived longer.

All these findings were in agreement with the foundations of their model, which stated that oxidative stress and protein instability increase with age and are the root cause of cell degeneration.

This modeling is unique by being mathematically detailed and describing a broad range of cellular processes across the cells whole proteome [all proteins found in a cell], Ken A. Dill, PhD, a distinguished professor and director of the Laufer Center for Physical & Quantitative Biology, and a study co-author, said in a news release.

Often, aging-related studies look at the effects of one or two proteins at a time, rather than seeking, more generally, the cellular aging mechanism itself, Dill added.

This study also sets the foundation for future research into the molecular origins of aging disorders associated with protein misfolding, such as Parkinsons.

Joana holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. She is currently finishing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that made up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Continued here:

Insights into Parkinson's Onset May Lie in New Model of Cell Aging and Damage - Parkinson's News Today

RNA Folding Insights Lead to New Therapeutics and Synthetic Biology Technologies – Technology Networks

A Northwestern Engineering research team led by Professor Julius Lucks has uncovered a new understanding of how RNA molecules act as cellular 'biosensors' to monitor and respond to changes in the environment by controlling gene expression. The findings could impact the design of future RNA-specific therapeutics as well as new synthetic biology tools that measure the presence of toxins in the environment.

RNA molecules play a pivotal role in storing and propagating genetic information like DNA, as well as performing functions critical to living systems like proteins. At the core of its function is its ability to undergo origami-style folding into intricate shapes inside the cell.

Using high-throughput next-generation sequencing technology developed in his lab that chemically images the dynamic shapes RNAs fold into, Lucks found similarities in the folding tendencies among a family of RNA molecules, called riboswitches. Riboswitches act as natural biosensors to monitor the internal and external state of cells. When a riboswitch binds to a molecule, it changes its shape, causing a change in gene expression.

"These riboswitches have evolved to fold into very specific shapes so they can recognize other compounds, change their shape when they bind to them, and ultimately induce a change in gene expression," said Lucks, associate chair and professor of chemical and biological engineering at the McCormick School of Engineering. "There's been little studied about how exactly they can fold and adjust those shapes, especially since they do so before the RNAs are fully made. We learned that there is an evolutionary pressure on RNAs to not only fold into the final structure, but to have a pathway to do so similarly and efficiently."

A paper outlining the work, titled "A Ligand Gated Strand Displacement Mechanism for ZTP Riboswitch Transcription Control," was published on October 21 in the journalNature Chemical Biology. The study was also featured in the journal's "News & Views" section.

Lucks served as the paper's corresponding author, while Eric Strobel, a Beckman Postdoctoral Fellow in Lucks's group, served as the study's lead author. PhD students Katherine Berman and Luyi Cheng, and visiting predoctoral scholar Paul Carlson, all from the Lucks Lab, also contributed to the research.

The study builds on past research in which Lucks and his team developed a platform that provides super high-resolution representations of RNA shape changing as the RNAs are synthesized.

Finding Folding SimilaritiesPreviously, Lucks and his team used their high-resolution system to study how a riboswitch sensed the fluoride ion. In theNature Chemical Biologypaper, he applied the system to a riboswitch responsible for sensing a natural cellular alarmone molecule called ZTP, which Lucks said functions as an "alarm trigger" in cells.

Despite structural and functional differences between the riboswitches and their respective target compounds, Lucks discovered that in both instances the riboswitches followed the same folding pathway -- the series of shapes the RNA molecule progresses through as it is synthesized.

Using high-throughput next-generation sequencing technology, Professor Julius Lucks found similarities in the folding tendencies among a family of RNA molecules, called riboswitches.

"Once RNAs are made, they immediately fold into a shape that recognizes the molecule. If the molecule is there, the shape locks in and preserves the structure," Lucks said. "If the molecule isn't present, the RNA unravels itself. We found that happened in both instances.

"Whether you're trying to make an origami crane or frog, the first several steps are pretty much the same," he added. "While these RNAs look different, they're amazingly similar when you break them down into their sequence of folding instructions. Finding links to these common features lays the groundwork for coding these principles as design elements for when we want to harness them for our own uses."

Those uses could include future drug delivery strategies. While many therapeutics are designed to treat diseases caused by protein misfolding, such as Alzheimer's or Parkinson's, Lucks believes his lab's work could inform efforts to treat diseases believed to be triggered at the RNA level, including spinal muscular atrophy, a neuromuscular disorder caused by the mis-splicing of the SMN gene.

"You may not only want to target the final structure of an RNA molecule, because they all fold in some sort of structure, but also the folding process to get into that structure," he said.

The findings also represent a positive step toward harnessing RNA's capability as a natural biosensor. Working with Northwestern's Center for Synthetic Biology and Center for Water Research, Lucks and his lab are pursuing how riboswitches could be used within low-cost synthetic biology platforms to detect toxins in the environment, impacting areas like crop health and water quality.

"As we learn more about the architecture behind how RNAs work, we'll seek to understand how to make them work better," Lucks said. "Nature may have evolved to make them do one thing, but we want them to work for us faster or more sensitively. We're still learning how to do that, but we're nearing that level of detail where we can truly design around these principles."

Reference: Strobel et al. 2019.A ligand-gated strand displacement mechanism for ZTP riboswitch transcription control. Nature Chemical Biology.DOI: https://doi.org/10.1038/s41589-019-0382-7.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Excerpt from:

RNA Folding Insights Lead to New Therapeutics and Synthetic Biology Technologies - Technology Networks

The Hidden Inactive Ingredient: Biological Products in Recombinant Pharmaceuticals – P&T Community

INTRODUCTION

Pharmaceutical products have long been prepared with various inactive ingredients to enhance pharmacokinetics, stability, and pharmaceutical elegance. In an age where the use of recombinant technologies is rapidly increasing and consumers are more aware of inactive ingredients in food and cosmetic products, there remains a paucity of centralized information to help medical professionals counsel their patients about recombinant technologies. Although patient-specific factors such as race, age, and weight are considered when prescribing and dispensing medications, oftentimes religion and dietary habits are left out of the conversation. The increasing array of biopharmaceuticals on the market and in production creates an opportunity for healthcare providers and patients to enhance their knowledge of these issues. The purpose of this review is to create a centralized resource for healthcare providers that describes some common dietary restrictions of select faith and ethnic groups and to identify FDA-approved medications of biologic origin.

A biopharmaceutical is any active agent biological in nature and manufactured using living organisms.1 Since the 1980s, scientists have been harnessing the power of single-cell organisms to create unique proteins that can be used to treat a wide range of disease states ranging from diabetes to hematologic disorders. The recombinant process enhances scientists ability to modify and manipulate protein structure and function to produce a targeted agent for therapeutic purposes. Now, almost 40 years later, recombinant technologies are on the rise using a wider range of bacterial, fungal, and animal cell lines.1,2

Original biopharmaceuticals were replacement proteins such as insulin, hormones, and antibodies. Advancements in the field have widened the scope of indications to hematologic and oncologic disorders. Recombinant products for use in oncology have been expanding over the past two decades, with a focus on monoclonal antibody production. The area of targeted drug delivery within oncology is a rapidly growing field, with promise for new agents or enhancements to existing agents that can improve antitumor cytotoxicity while reducing adverse effects. As this technology continues to advance, scientists are experimenting with alternative ways to produce biopharmaceuticals by way of transgenic organisms and animal cloning.3

The process of creating a recombinant product involves transferring the specific genes responsible for creating the protein into a bacteria, yeast, or animal cell. Historically, Escherichia coli was the prominent cell line that was used, and even today is the cell line used to manufacturer medications such as insulin and filgrastim. Over time, scientists explored the use of yeast cells, namely Saccharomyces cerevisiae, and other mammalian cells such as Chinese hamster ovary (CHO) cells.

The use of mammalian cell lines has increased in recent years because of the cell systems ability to produce glycosylated proteins.2 Glycosylation is one of the most complex post-translational modifications that occurs to a protein but it offers certain pharmaceutical advantages, such as increased plasma half-life.4 Many antibodies that were formed as a result of recombinant technology combine fragments from two different species. Often, these are combined with human fragments to form chimeric antibodies. Most commonly, murine antibody fragments have been fused with human fragments to produce an antibody that is more human-like. This differs from a humanized antibody, which may contain elements of nonhuman origin but maintains essentially the same amino acid sequence that can be found in the human antibody.5 Irrespective of drug development, a pharmaceutical manufacturers choice of cell line is balanced by the complexity of protein folding and post-translational modifications with a cell line that is easy to maintain and simple to culture.

The nomenclature of recombinant products is regulated by the World Health Organization (WHO)s International Nonproprietary Names (INN). Names awarded an INN are selected by WHO on the advice of experts from the organizations Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations.

The product names can assist health practitioners in understanding how the products are manufactured based on the pre-stems and stems of the names.6 It is beyond the scope of our review to discuss all the nomenclature, but monoclonal antibody medications are a good example of this practice. Previously, two infixes denoted the target of the drug as well as the source. In 2015, the INN together with the United States Adopted Name (USAN) Council agreed that to simplify drug naming, the source infix would be dropped.5 The name now consists of a prefix, a target infix, and the suffix -mab (Table 1).

Often the most convenient source of information on how a drug is manufactured is the package insert. However, information about the recombinant process and the cell line from which the pharmaceutical product is made frequently isnt relayed to the patient during counseling. To compile a compendium of medications from animal origin, we undertook an extensive review of all Food and Drug Administration (FDA)-approved medications using a data set of 15,797 entries based on the National Drug Code (NDC) from the FDA website, on December 2, 2016.7 Duplicate entries based on nonproprietary names were deleted. We also initially excluded entries whose marketing category included cosmetic, over-the-counter (OTC) drug monograph, unapproved homeopathic, or unapproved medical gas, and entries whose product type was a standardized or non-standardized allergenic extract. The remaining 666 records we reviewed manually, and we also reviewed package inserts for possible inclusion. Table 2 is organized by the type of cell line used in the manufacturing process, listed alphabetically by generic name.

Additional ingredients involved in the preparation of pharmaceutical products also may be derived from animal products. Gelatin is a substance of bovine or porcine origin that is commonly used for commercially made capsules.8 A WHO memo from 2001 addresses a ruling that allows Muslims to accept gelatin because it has been transformed from its original source,8,9 although not all Muslims accept the ruling. Specialized compounding centers may offer vegetable-based capsules for those who refuse gelatin-based products.

Lactose is a common sugar that is found as a filler in many capsules and tablets and is derived from cows milk. In addition, lactulose can be synthetically produced in large quantities in the laboratory. Lanolin is a fat extracted from sheeps wool that is used as an ingredient and base in many ointments and topical medications. It is important to consider all ingredients within a pharmaceutical preparation, including all the inactive ingredients.8

It is well known within the medical community that Jehovahs Witnesses patients abstain from blood products. This issue often comes to a head when a patient is critically ill and in need of a transfusion. Many hospitals have developed policies and standard procedures for approaching these situations to respect the autonomy of the patient while continuing to offer appropriate and excellent medical care. Although this restriction is widely known, providers might not be so familiar with other, less common restrictions.

Even within a faith or ethnic group there can be differences about dietary restrictions, but having a general sense of what these restrictions are will enable providers to provide a patient-centered care approach. A lack of communication might lead to distrust and decreased patient satisfaction if a patient subsequently learned how a particular medication is processed and handled.

The decision to adhere to strict dietary restrictions is an individual choice. Through conversations with the patient, a provider can identify the personal dietary beliefs that might affect their therapy selection. Certain religious organizations have thus made formal statements to relieve their followers of strict dietary considerations as they relate to medicine and health. For example, Muslims are permitted to ingest gelatin capsules because the product is believed to be transformed in property and in character. Shariah law also allows for the use of insulin products in case of necessity.9 Table 3 lists common religious and faith-based groups that follow specific dietary restrictions.8,1215 It is important to note that within these general classifications, there are also various practices arising from individual beliefs.

There is no consensus on how to deal with patient refusal based on faith or ethnic beliefs. Because adherence to diet that is based on religion is personal to the patient, it requires a personal response from the provider. Oftentimes, a patients refusal to use a specific product can be met with misunderstanding and frustration by the provider. Sometimes a conversation about the risks and benefits can persuade the patient to adhere to a medication while at other times, frank refusal can lead to patient morbidity and mortality. In certain situations, it would be appropriate to routinely solicit information regarding religious or personal prohibitions in order to identify potential conflicts with the treatment plan. Maintaining open communication with the patient can prevent such conflicts. In the authors experience, patients also may be misinformed about specific pharmaceuticals as a result of their own Internet searches; this can make them hesitant to trust the healthcare team, who can provide them with well-researched information. When confronted with these situations, the goal of healthcare professionals should be to provide their patients with treatment options and sound medical advice while simultaneously respecting patients autonomy when they make their decisions.

Consider the following example of an individual who abstains from pork products. Patients receiving dialysis must have their hemodialysis catheter flushed and locked with an anticoagulant solution to maintain the catheters patency. Normally, heparin locks are the anticoagulant of choice for this indication, but patients who strictly adhere to pork restrictions may refuse these. Heparin in central venous lines is more effective than normal saline at reducing the amount of line occlusions.10 Sodium citrate might be another option but it will present additional challenges because of procurement and availability.11 Additional options and their risks and benefits can be discussed with the patient to ensure a solution is found that meets everyones needs.

As technological advances enhance the ability of researchers and healthcare professionals to provide medications that target specific receptors, the challenge will be to provide consistent and relevant information to the patient. Providers may encounter the need to discuss a patients personal beliefs and opinions of medication-manufacturing processes while they are administering health care. A regularly updated, centralized resource that is easily accessible to providers at the point of treatment is necessary to help inform patients about their healthcare decisions. Although patients decisions and beliefs can be misunderstood by and prove frustrating for providers, this knowledge will help to prepare and facilitate a productive discussion regarding patients desired outcomes.

Disclosure: The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria.

Read the original:

The Hidden Inactive Ingredient: Biological Products in Recombinant Pharmaceuticals - P&T Community

Two years in the making, Pizza Hut tests a round pizza box – Fast Company

This week, Pizza Hut is using one Phoenix location to test two innovations. First up is a trial of plant-based Italian sausage as a pizza topping on a Garden Specialty Pizza, complemented by banana peppers, onions, and mushrooms. The sausage is made by Kelloggs incomparably named Incogmeato brand. Pizza toppings made from plant-based meat are still rather novel; in the United States, only Little Casears has tested an Italian sausage crumble from Impossible last spring.

But while the protein may top a lot of the headlines, the real potential for change is in its second move here: a round pizza box.

According to Pizza Hut,the new box keeps pizzas crispier, and it relies on less overall packaging compared with a typical square pizza box. The companys chief customer and operations officerNicolas Burquier says Pizza Hut worked with the startup Zume, best known for robotic pizza trucks, for more than two years on this design.

The goal was to design a box that simply makes our pizza taste even betterhotter pizza, crispier crust, says Burquier. This box will improve the pizza-eating experience for our customers and simplify operations for our team members.

The new round box has grooves to help catch grease and prevent soggy crust, and the top latches to keep heat in. It also interlocks easily to stack compactly, cutting out the employee effort that typically must be devoted to folding pizza boxes.

It may be innovative, but Pizza Hut is hardly the first to cut the corners off its pizza boxes. Back in 2010, Apple actually filed a patent for a round pizza box of its own, then touted it in a fun, three-minute ad called The Underdogs back in April.

In 2018, sustainable packaging company World Centric unveiled its own version of the round box. And even way back in 2004, a round pizza box called the Presseal was introduced by an inventor named John Harvey. None managed to catch on at a scale that even comes close to threatening the dominance of the almighty square.

ButBurquier is confident that could change.

One day in the future well reminisce about the idea of round pizzas in square boxes and laugh,says Burquier. The company plans to evaluate how the limited rollout in Phoenix goes, and look for ways to expand it across the country.

Continue reading here:

Two years in the making, Pizza Hut tests a round pizza box - Fast Company

Fava Is All About Balance – East Bay Express

Some chefs dream of white tablecloth, three-Michelin-star glory. But Sylvie Osborne-Calierno and Jeremy Scheiblauer, a duo of chefs and best friends, had other plans in mind.

"We always knew we wanted a tiny little spot," Osborne-Calierno said. So when they heard that the 42-year-old Juice Bar Collective on Vine Street was closing, they jumped at the chance to carve out their own tiny slice of North Berkeley.

It's not that Osborne-Calierno and Scheiblauer lacked the pedigrees to open a larger restaurant. The friends met cooking at Chez Panisse 12 years ago, and both went on to open other restaurants Osborne-Calierno with Toto, a brunch restaurant in Barcelona, Spain, and Scheiblauer with Heyday, a lunch spot in San Francisco's Financial district. Both ultimately returned to Chez Panisse, where they were working until Fava's opening.

Alice Waters' guiding principles are evident in the food that comes out of Fava's kitchen: the insistence upon fresh, top-quality ingredients, simply prepared without relying on fancy equipment. But Fava drops the French cooking techniques, the four-course format, and the triple-digit price tag in favor of a shoebox-sized, counter-service only restaurant, equipped with compostable plates and a few outdoor folding tables and chairs.

With such a small space, the duo had to pare down Fava's menu to just the essentials: a few salads, sandwiches, and a daily soup, plus fresh juices and sesame-chocolate chip cookies.

"It really gives you constraints that sometimes maybe feel a little tight," Osborne-Calierno said. "But at the same time, it really forces you to really hone down and get to the real soul of what you're trying to do."

Fava's style isn't easy to distill into a few words or labels, but the menu, which happens to be entirely housemade and organic, is clearly Mediterranean and Middle Eastern influenced. Latin American influences also make their way onto the menu, albeit more subtly. "We don't really feel pegged to any one culture," Osborne-Calierno said. "We just make things that taste good."

The lamb flatbread is one of the restaurant's best sellers, and for good reason. The bread itself, which lies somewhere between naan and pita, is made in-house every day with whole wheat flour. The last bit of cooking gets done on a plancha, giving it the same effect as freshly made bread. The bread was delightfully airy, chewy, and elastic, with a touch of crispness around the edges and a nutty, toasty flavor. On top of the flatbread was a smear of harissa, which lent bright color and a punch of cumin. Layered on top of that were tender, juicy slices of lamb shoulder braised in a tomatoey broth "grandma-style," Osborne-Calierno calls it, as opposed to French cooking techniques that incorporate mirepoix and wine. Dollops of creamy, rich yogurt topped the lamb, followed by crunchy red cabbage tossed with a touch of vinegar. The crowning glory was a copious handful of mint, dill, and cilantro.

At first, I was taken aback by how many herbs were on top of the flatbread, and since you're eating it open-faced, you're likely to end up with an entire sprig of mint sticking out of your mouth at some point. But the whole thing was surprisingly well-balanced, and it struck me how the herbs and vegetables shone just as brightly as the lamb. The herbs also kept the sandwich light and refreshing, which was a minor miracle considering that lamb is such a fatty, richly flavored protein. "We don't believe in there being too [many] herbs," Osborne-Calierno laughed. "We like to treat herbs like they're a lettuce, like they're a vegetable."

Fava's menu is primarily vegetable-focused every other item on the menu when I visited was vegetarian. I particularly enjoyed the escarole salad. The slight bitterness of the crisp, lightly dressed leaves was perfectly balanced by slices of juicy melon, while housemade chile almonds added a little earthiness and spiciness. Bulgur wheat served double duty, not only by making the salad more filling, but also by brightening it up with plenty of lemon juice. The most striking part was the leaves of purple basil on top, which added an unexpected pop of color and flavor.

"I like the purple basil ... it kinda looks crazy," said Osborne-Calierno. "[We] kinda try to be a little crazy, spice up North Berkeley a little bit."

Also on offer was a hummus bowl with roasted eggplant, topped with cherry tomatoes, French feta, red cabbage, and purslane. The hummus was exceptionally smooth with plenty of tahini flavor, while the golden tomatoes were firm and perfectly ripe. I appreciated the use of French feta here, which provided a punch of salt with a creamier, milder flavor than its Greek and Bulgarian counterparts. Like all the other dishes I tried, it was also a beautiful dish to look at, with the green purslane and purple cabbage dominating the dish with little golden tomatoes shining like gems amid a background of hummus.

For maximum Instagrammability, try one of the brightly colored yet not-too-sweet housemade juices to enhance the look of your meal. I particularly loved the mango lassi, which was creamy and tangy with plenty of real mango flavor. The hibiscus lemonade and green juice, on the other hand, were refreshing and tart.

A rotating selection of soups and sides rounds out the menu. I wasn't a big fan of the side of roasted sweet potatoes. Though they were perfectly roasted and caramelized, they needed a little salt for balance.

The soups, though, are worth ordering. On one of my visits, it was a warm tomato soup with firm chickpeas and a dollop of zesty, creamy lime yogurt; on another, it was a red lentil soup topped with a drizzle of lemon oil for an unexpected citrusy kick.

Don't leave Fava without one (or more) of the sesame chocolate chip cookies. The sesame provided a nutty flavor and subtle richness to the cookie, while giving it a chewier-than-usual texture. Best of all, the cookies used dark chocolate wafers rather than chocolate chips, which provided luscious pools of fruity, bitter dark chocolate.

No, it's not health food. But like everything else at Fava, it's all about balance. Asked whether Fava will open for dinner one day, the duo said they'd like to stick to lunch hours and possibly breakfast one day so they can balance cooking with having an actual life outside of the kitchen, which is a rarity in the restaurant industry.

Osborne-Calierno is the mother of 5-year-old twins. When Scheiblauer isn't cooking in the kitchen, he's busy playing synths in his post-punk, new wave band called Vandal Moon. Sure, the duo is ushering a youthful, casual vibe with plenty of fresh flavors into North Berkeley but unlike generations before them, they won't sacrifice having a balanced lifestyle.

"I don't think moms should have to choose between 'I'm either a mom or I'm a chef,'" Osborne-Calierno said. "We are all these things at once, and that's really important."

Go here to see the original:

Fava Is All About Balance - East Bay Express

Amazon fish wears nature’s ‘bullet-proof vest’ to thwart piranhas – Reuters

WASHINGTON (Reuters) - One of the worlds largest freshwater fish is protected by the natural equivalent of a bullet-proof vest, helping it thrive in the dangerous waters of the Amazon River basin with flexible armor-like scales able to withstand ferocious piranha attacks.

FILE PHOTO: Diver Alex Reeson checks on the Arapaima or Pirarucu fishes in the tropical section of Europe's biggest freshwater aquarium Aquatis, due to open October 21, in Lausanne, Switzerland October 17, 2017. REUTERS/Denis Balibouse/File Photo

Researchers from the University of California, San Diego and University of California, Berkeley on Wednesday described the unique structure and impressive properties of the dermal armor of the fish, called Arapaima gigas. They said their findings can help guide development of better body armor for people as well as applications in aerospace design.

The fish, also known as pirarucu, gets up to 10 feet (3 meters) long and weighs up to 440 pounds (200 kg). Arapaima, a fish that can breathe air and survive up to a day outside of the water, inhabits rivers in Brazil, Guyana and Peru infested with piranhas, known for razor-sharp teeth, incredible bite strength and deadly feeding frenzies.

There long has been an evolutionary arms race in which predators develop ways to kill - like sharp teeth - and other animals develop ways to stay alive like the dermal armor seen in various fish, dinosaurs and mammals over time. Arapaimas scales, the researchers said, possess all the best attributes of a bullet-proof vest, but the elements are better integrated into one solid piece combining imperviousness and flexibility.

Such lightweight and tough materials like fish scales are the sexy topics that materials scientists are pursuing, said Wen Yang, a UCSD materials scientist who helped lead the study published in the journal Matter.

It is true that the natural armor is similar to artificial body armor because of the similar scale overlapping system. However, the natural armor such as these fish scales is tough and much lighter, without impeding body flexibility and locomotion, Yang added. Remember that the fish scales were developed through hundreds of millions of years. They are very advanced.

The researchers conducted laboratory tests of the scales.

The scales, they found, have a hardmineralized outer layer to resist penetration that is bound to a tough-but-flexible inner layer by collagen themain structural protein in skin and other connective tissues in the body.

This structure means the scales can become deformed when bitten by a piranha but are not torn, broken or pierced, protecting the fish from injury.

We were able to see how the collagen fibers deform without a catastrophic failure including the mechanisms of twisting, folding, sliding, stretching, delamination, Yang said.

The study was backed by the U.S. Air Force Office of Scientific Research.

Reporting by Will Dunham; Editing by Sandra Maler

Read more:

Amazon fish wears nature's 'bullet-proof vest' to thwart piranhas - Reuters

Global Longevity & Anti-Senescence Therapy Market Review 2017-2018 and Forecast to 2023 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Global Longevity and Anti-Senescence Therapy Market" report has been added to ResearchAndMarkets.com's offering.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on the study of genomics, microbiome, bioinformatics, and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy, and Others. Senolytic drug therapy held the largest market revenue share in 2017. The fastest growth of the gene therapy segment is due to the Large investments in genomics.

Report Scope

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023.

The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

The report includes:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Global Longevity and Anti-senescence Market by Therapy

Chapter 5 Global Longevity and Anti-senescence Market by Application

Chapter 6 Global Longevity and Anti-senescence Market by Region

Chapter 7 Industry Structure in Longevity and Anti-senescence Market

Chapter 8 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/zy7jt

More:

Global Longevity & Anti-Senescence Therapy Market Review 2017-2018 and Forecast to 2023 - ResearchAndMarkets.com - Business Wire

LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology – PRNewswire

PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow functioning organs within a patient's own body. This financing will enable LyGenesis's lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020.

"We have advanced our liver regeneration program through preclinical trials and this financing will help us to rapidly transition into a clinical-stage biotechnology company," said Michael Hufford, PhD, Co-Founder and CEO of LyGenesis. "Our ability to use the lymph node as a bioreactor for organogenesis is also generating interest from partner companies looking for an enabling technology so that their genetically modified cell therapies are able to engraft, proliferate, vascularize, and produce a therapeutic effect in patients."

"We are thrilled to continue our financial support of LyGenesis as they transition into clinical development," said Greg Bailey, MD, Co-Founder and CEO of Juvenescence, and a member of LyGenesis's Board of Directors. Sergey Young, founder of Longevity Vision Fund, said "The ability to regenerate functioning ectopic organs was science fiction just a few short years ago. The progress of LyGenesis's technology is emblematic of the rapid advances we are witnessing as biotechnology transitions from bench research, to preclinical models, and now into the clinic."

About LyGenesis, Inc.LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

About Juvenescence, Ltd.Juvenescence Limited is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. To learn more, please visit juvenescence.ltd.

About Longevity Vision FundLongevity Vision Fundis a $100M life extension-focused investment fund dedicated to making longevity affordable and accessible to all. Founded by Sergey Young, the fund accelerates breakthroughs in longevity by investing in start-ups and companies that develop technologies, products, and services that extend human lifespans and overcome the negative effects of aging. The Fund provides funding to biotech and life extension-focused companies developing early diagnostics, AI in healthcare, and therapies addressing age-related diseases. To learn more, please visit lvf.vc.

Media Contact:Michael Hufford, PhD+1.858.603.2514226496@email4pr.com

SOURCE LyGenesis, Inc.

http://www.lygenesis.com

See more here:

LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology - PRNewswire

Opinion: Entrepreneurs and Their Startup Businesses Need San Diegos Support – Times of San Diego

Share This Article:Startup teams at an EvoNesus incubator in downtown San Diego. Photo by Chris JenneweinBy Duane Cameron

Everyone in business and economic development agree that startups are great for citiesbut how can communities and leaders do more than just tout the benefits of startups, and actually help pave the way for entrepreneurs to bring their business ideas to life?

Support Times of San Diego's growthwith a small monthly contribution

One way of getting behind San Diego startups is through celebrating the innovation and creativity being brought to our region. This month Cox Business, Tech Coast Angels and the San Diego Venture Group are doing exactly that by sponsoring and organizing the John G. Watson Quick Pitch Competition.

The Quick Pitch Competition on Oct. 29 gives 10 local startups the opportunity to compete for grants of up to $50,000 to further develop their idea. Its one of several others like it throughout the year here in our region.

However, we can always do more to support our startup ecosystemespecially if we want to hang on to our distinction as one of the best cities in America to launch a business. Moreover, San Diego in particular has a number of very good reasons to do so:

Small businesses, including startups, are the backbone of our regional economy. Small businesses, defined as those with 100 employees or fewer, employ697,000 people, or 59 percentof San Diegos workforce. If we were to attract fewer talented entrepreneurs, opportunities for both our long-time residents and recent transplants would dry up, and our economy would suffer.

Theyve given us our reputation as a life sciences and biotechnology innovation hub. Aside from the San Francisco Bay Area and the Boston-Cambridge region, were one of the top cities for manufacturing, testing and research in the fields of biotechnology, pharmaceuticals and medical devices. Several of the top employers in this area are, of course, large companies like Illumina, but a vast majority of the more than 1,100 life and sciences biotech businesses in San Diego began life as small startups with an idea.

They encourage competition. Competition is a good thing and spurs innovation, and a competitive business ecosystem makes our city stand out as a dynamic source of tech solutions. As Ben Yoskowitz, an angel investor and founding partner at Year One Labs puts it, Any reasonably good idea has 10,000 people working on it right now.

A few local startups have made it big already. Thanks to our large pool of talent both local and transplanted (the perks of being a major center for universities) as well as a good network of accelerators that coach startups on how to prepare for a successful launch, many of our startups have emerged as major players on the national scene. Think GoFundMe, Classy, Brain Corp, and Human Longevity. Imagine how many more ideas like these are currently incubating among San Diegos startup founders.

They employ talent from other tech hubs, especially recent graduates. The job market may have improved greatly since the 2008-2009 recession, and unemployment may be low, but its still challenging to get your foot in the door as a recent college graduate. In cities like San Diego, though, where theres a strong pool of startups, these young professionals can easily find employment that develops them professionally into the future talent that our city will need to continue to grow.

San Diego has steadily climbed higher on lists of top U.S. cities for startups over the past few years, but that didnt happen in a vacuum. Every big company started small, and its important that larger companies encourage startups, and help provide funding through programs such as the Quick Pitch Competitionespecially if theyre in your field. Its good for business and for everyone who lives and works in Americas finest region.

Duane Cameron has more than 30 years of experience in the telecommunications industry. He is vice president for Cox Business, helping to bring innovative products and services to Southern California businesses.

Opinion: Entrepreneurs and Their Startup Businesses Need San Diegos Support was last modified: October 17th, 2019 by Editor

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read the rest here:

Opinion: Entrepreneurs and Their Startup Businesses Need San Diegos Support - Times of San Diego

Overthinking Can Shorten Your Life, Says New Study – International Business Times

Although it is one natural ability of human beings to think and it is what sets us apart from animals, but when you get overboard with thinking, it can get detrimental. A new study suggests that overthinking can shorten your lifespan.

The study conducted by the researchers at Harvard Medical School has found that excessive brain activity could decrease ones lifespan. It involved individuals aged 60-70 years whose brains were compared to those who lived until they were 100 or more.

Their findings suggested that people who died at younger ages had significantly lower levels of the protein REST (RE-1 silencing Transcription)- one that silences your brain activity. Precisely, the study showed that overthinking causes excessive brain activity which in turn leads to depletion in ones REST protein levels and shortened lifespan. And that suppressing such overactivity extends life. Several other studies have also proved that REST protein offers protection against Alzheimers disease.

This is the first study to prove that the activity of the nervous system affects the longevity of human beings. Though several studies have previously reported the phenomenon among animals, the role of neural activity in human aging has remained murky until now.

The lead author Bruce Yankner, professor of genetics at HMS and co-director of thePaul F. Glenn Center for the Biology of Agingsaid,An intriguing aspect of our findings is that something as transient as the activity state of neural circuits could have such far-ranging consequences for physiology and life span. He added that they now have several individuals enrolled in such studies to partition the aging population into genetic subgroups. He also opines that this information is invaluable and makes it evident as to why it's so important to support the future of human genetics.

The study has paved the way for designing new therapies for health conditions that are associated with neural overactivity including Alzheimers disease and bipolar diseases. The study results also create the possibility that meditation or medicines that can target REST protein could extend the human life span by modulating neural activity.

"The possibility that being able to activate REST would reduce excitatory neural activity and slow aging in humans is extremely exciting," said the study co-authorMonica Colaicovo, professor of genetics at Harvard Medical School.

Overthinking Photo: Jambulboy, Pixabay

Originally posted here:

Overthinking Can Shorten Your Life, Says New Study - International Business Times